Clinical Trial Update: Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg [Phase 3]

View source ↗

Summary

A Phase 3 cross-over study in COPD evaluated lung function after treatment with umeclidinium, vilanterol, and the umeclidinium/vilanterol combination; results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Umeclidinium (umeclidinium)
• Umeclidinium/Vilanterol (umeclidinium/vilanterol)
• Vilanterol (vilanterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2014-02-11